Tango Therapeutics, Inc. TNGX
Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We leverage our state-of-the-art target and drug discovery platforms to identify novel disease-relevant targets and develop medicines tailored to defined patient populations with high unmet medical need. Our novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles, thus potentially maximizing clinical benefit.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M | $7.7M | — |
| R&D | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M | $50.0M | — |
| SG&A | $41.5M | $43.7M | $35.5M | $30.0M | $17.6M | $9.9M | — |
| Total operating expenses | $173.7M | $187.7M | $150.7M | $135.9M | $95.2M | $59.9M | — |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M | -$52.2M | — |
| Interest expense | $5.6M | $7.9M | $6.6M | $1.5M | $495.0K | $108.0K | — |
| Pre-tax income | -$101.6M | -$130.1M | -$101.6M | -$108.1M | -$57.9M | -$52.0M | — |
| Income tax | $4.0K | $208.0K | $134.0K | $54.0K | $292.0K | $0 | — |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M | -$52.0M | — |
| EPS, basic | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | — | — |
| EPS, diluted | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 | — |
| Shares, diluted (wtd. avg.) | 116.2M | 109.2M | 94.6M | 87.8M | 62.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $112.3M | $69.5M | $66.4M | $60.0M | $142.7M | $28.4M | — |
| Short-term investments | $230.9M | $188.4M | $270.5M | $306.2M | $342.5M | $161.9M | — |
| Receivables | — | — | — | $2.0M | $2.0M | $2.0M | — |
| Total current assets | $353.8M | $266.3M | $346.5M | $375.3M | $492.3M | $193.6M | — |
| Property, plant and equipment | $6.9M | $8.1M | $9.9M | $10.9M | $4.8M | $3.8M | — |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M | $207.3M | — |
| Accounts payable | $1.2M | $1.6M | $2.8M | $4.5M | $3.2M | $1.8M | — |
| Total current liabilities | $21.7M | $38.2M | $45.9M | $55.5M | $40.7M | $40.9M | — |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M | $168.7M | — |
| Retained earnings | -$603.2M | -$501.6M | -$371.3M | -$269.5M | -$161.3M | -$103.1M | — |
| Total equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M | $38.6M | $7.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M | $70.1M | — |
| Depreciation and amortisation | $2.3M | $2.5M | $2.4M | $1.6M | $897.0K | $718.0K | — |
| Stock-based compensation | $26.4M | $28.9M | $19.1M | $14.2M | $7.8M | $1.8M | — |
| Capital expenditure | $1.0M | $754.0K | $1.5M | $7.7M | $1.8M | $1.1M | — |
| Investing cash flow | -$40.9M | $86.1M | $41.4M | $26.4M | -$183.4M | -$145.5M | — |
| Financing cash flow | $222.5M | $47.7M | $82.4M | $1.6M | $357.3M | $80.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-160287.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $7.7M | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$52.0M | -$58.2M | -$108.2M | -$101.7M | -$130.3M | -$101.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |